DRUG · Unmapped registry intervention
BHV-0223
Find medicine records ·
Find other trials using this name
Clinical trial
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
NCT03520517
Study summary
ClinicalTrials.govOpen-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Advertisement
Conditions
ALSverified · MONDO: amyotrophic lateral sclerosis
Lou Gehrig's Diseaseunresolved
Lou-Gehrigs Diseaseunresolved
Interventions
BHV-0223DRUG
Sponsors & collaborators
Biohaven Pharmaceuticals, Inc.lead sponsor
Cognitive Research Corporationcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03520517 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.